CVRx, Inc. announced on February 12, 2025, the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The study, simultaneously published in the Journal of Cardiac Failure, demonstrated substantial reductions in hospital visits and length of stay following Barostim implantation.
The analysis utilized data from the Premier Healthcare Database, encompassing over 1,300 institutions and 306 Barostim patients. Comparisons were made for the 12 months prior to implantation versus an average of almost two years post-implant.
Key findings included an 85% reduction in heart failure hospital visits, an 84% reduction in cardiovascular hospital visits, and an 86% reduction in all-cause hospital visits. These statistically significant outcomes highlight Barostim's potential to improve patient quality of life and reduce healthcare costs, providing critical evidence for clinicians and payers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.